Stephanie Koch Selected Research

COVID-19

1/2022

Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephanie Koch Research Topics

Disease

2	Sepsis (Septicemia) 08/2018 - 01/2016
1	COVID-19 01/2022
1	Peripheral Nerve Injuries 12/2008
1	Neuralgia (Stump Neuralgia) 12/2008
1	Sleep Initiation and Maintenance Disorders (Insomnia) 03/2002

Drug/Important Bio-Agent (IBA)

1	Antiviral Agents (Antivirals)IBA 01/2022
1	CytokinesIBA 01/2022
1	EnzymesIBA 01/2022
1	Interferon-gamma (Interferon, gamma)IBA 01/2022
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2016
1	Nerve Growth Factors (Neurotrophins)IBA 12/2008
1	NeuropeptidesIBA 12/2008
1	Peptides (Polypeptides)IBA 12/2008
1	VGF peptideIBA 12/2008
1	Amino Acids FDA Link 03/2002
1	Tryptophan (L-Tryptophan)FDA Link 03/2002

Therapy/Procedure

2	Bioreactors (Bioreactor) 08/2018 - 01/2016
1	Therapeutics 01/2016